OneSource Specialty Pharma Limited announced its audited standalone and consolidated financial results for the quarter and year ended March 31, 2026. The Board of Directors, meeting on May 13, 2026, approved the results and appointed B S R & Co. LLP as statutory auditors, replacing Deloitte Haskins & Sells. The company reported a strong sequential recovery in Q4FY26, with consolidated revenue rising 47% quarter-on-quarter to ₹4,282.17 million, driven by growth across all service offerings and the India semaglutide commercial launch. EBITDA for the quarter expanded to ₹919 million, with margins improving to 21%. However, for the full fiscal year FY26, the company reported a consolidated net loss of ₹738.03 million compared to a net loss of ₹172.81 million in the previous year.

Q4 Performance

The quarterly performance reflected significant operating leverage on higher Contract Service Agreement (CSA) revenues. Revenue for Q4FY26 was ₹4,282.17 million, up from ₹2,903.40 million in Q3FY26. EBITDA increased to ₹919 million from ₹173 million in the previous quarter. On a reported basis, PAT was ₹45.97 million, a turnaround from a loss of ₹886.99 million in Q3FY26. The company attributed the growth to successful semaglutide launches in India across multiple customer brands, alongside new launches in the US injectables and soft-gelatin businesses.

Full-Year Financial Performance

For the full fiscal year FY26, consolidated revenue from operations stood at ₹14,215.90 million, a marginal decline from ₹14,448.53 million in FY25. The company reported a consolidated net loss of ₹738.03 million for FY26, compared to a net loss of ₹172.81 million in the previous year. Adjusted PAT for the year was ₹739 million, with an adjusted EPS of ₹6.5, compared to ₹21.0 in FY25. The decline in full-year profitability was attributed to a softer second half impacted by delayed semaglutide approvals in Canada and an elevated cost base due to the ramp-up of the DDC facility.

Standalone Financial Highlights

On a standalone basis, revenue from operations for Q4FY26 was ₹4,189.62 million, compared to ₹2,902.20 million in Q3FY26 and ₹4,774.14 million in Q4FY25. Standalone profit after tax for Q4FY26 was ₹214.79 million, a turnaround from a loss of ₹621.85 million in Q3FY26. For the full year, standalone revenue from operations stood at ₹14,053.81 million versus ₹12,995.89 million in FY25, with standalone profit after tax of ₹212.10 million compared to ₹200.00 million in FY25.

Auditor Appointment

The Board approved the appointment of B S R & Co. LLP (Firm's Registration No.: 101248W/W-100022) as the statutory auditors of the company, to hold office from the conclusion of the 19th Annual General Meeting for a term of five consecutive years, subject to shareholder approval. This replaces Deloitte Haskins & Sells (Firm Registration No. 008072S), whose term is ending at the ensuing annual general meeting. Deloitte Haskins & Sells issued an unmodified opinion on the audited financial results for the year ended March 31, 2026 and an unmodified conclusion in respect of the limited review for the quarter ended March 31, 2026.

Regulatory Filing

In compliance with Regulation 47 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, OneSource Specialty Pharma published a newspaper advertisement on May 14, 2026 in the Financial Express and Lokmat. The advertisement provided an extract of the audited financial results for the quarter and financial year ended March 31, 2026.

OneSource Specialty Pharma Limited has reported its audited financial results for the quarter and financial year ended March 31, 2026. The company announced a strong sequential recovery in Q4FY26, driven by the commencement of commercial shipments for drug device combinations and the launch of generic Semaglutide in India.

Financial Performance

For the fourth quarter, revenue stood at INR4,282 million, reflecting a 47% sequential growth. On a full-year basis, the company reported INR14,216 million in revenue, a 2% decline year-on-year attributed to delayed approvals in the previous quarter.

Profitability saw a sharp rebound in Q4. EBITDA was reported at INR919 million, expanding by more than 5x sequentially with margins increasing by 1,550 basis points. Adjusted Profit After Tax (PAT) for the quarter was INR390 million compared to a loss in the previous quarter. For the full year FY '26, adjusted PAT stood at INR739 million.

Operational Highlights

The company confirmed that its new manufacturing line is currently undergoing qualification and is expected to be available for commercialization in Q2FY27. Management noted that the current line is fully committed. The biologics business continues to generate significant interest, with the funnel expanding 4x versus the previous year.

Strategic Guidance

Management reaffirmed its long-term guidance for FY '28, targeting US$400 million in organic revenue with approximately 40% EBITDA margins. The company also announced the deferral of a previously announced scheme to acquire the injectables business of Steriscience and Brooks, citing valuation concerns and a focus on delivering the FY '28 guidance.